Get the Daily Brief
Latest Biotech News
Fujifilm opens UK mega‑CDMO — single‑use capacity expands
Fujifilm Biotechnologies opened an expanded Teesside site in the U.K., funded by roughly £400 million, and launched what it calls the country’s largest single‑use CDMO facility. The site adds...
Europe’s VCs form coalition to fix life‑sciences funding gap
A coalition of leading European venture capital firms launched the European Life Science Coalition (ELSC) to improve capital allocation and institutional investment conditions across the...
AI targets biology: yeast DNA and antibiotic discovery
MIT researchers trained AI models to learn yeast DNA sequences and optimize protein production workflows, aiming to lower costs in vaccine and biopharmaceutical manufacturing. The model decodes...
New algorithm assembles near‑complete genomes without ultra‑long reads
Haoyu Cheng of Yale developed hifiasm (ONT), an algorithm that reconstructs near end‑to‑end human genomes using standard sequencing inputs, removing the need for ultra‑long DNA extractions that...
First cell‑type gene regulatory map for Alzheimer’s built with SIGNET
A University of California, Irvine team introduced SIGNET, a machine‑learning framework that infers cell‑type‑specific gene regulatory networks in Alzheimer’s disease and identifies causal 'hub'...
China NMPA clears Gensci‑136 for IgA nephropathy trials
Changchun Genescience Pharma received NMPA clearance to initiate clinical trials of Gensci‑136, a dual APRIL/BAFF antagonist formulated for injection to treat immunoglobulin A nephropathy (IgAN)....
AI learns yeast DNA language: boosts protein drug output
MIT chemical engineers trained an AI model to read and optimize yeast DNA sequences to improve protein production yields used in vaccines and biopharmaceutical manufacturing. The work aims to...
FDA rejects Disc’s bitopertin — agency demands clinical endpoints
The FDA issued a complete response letter rejecting Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP), citing uncertainty that the drug’s surrogate biomarker (percent change in...
Gilead buys China cancer asset: $80M upfront, $1.45B in milestones
Gilead acquired global rights to Genhouse Bio’s clinic-ready MAT2A-targeting synthetic‑lethality candidate GH31, paying $80 million upfront and up to $1.45 billion in milestones plus double-digit...
Fujifilm opens UK mega‑CDMO: single‑use capacity and process hub
Fujifilm Biotechnologies inaugurated an expanded Teesside site after a roughly £400 million investment, opening what it calls the UK’s largest single‑use biopharma CDMO and a Bioprocess Innovation...
FDA turmoil: senior resignations and ethics complaints roil agency
Former CDER chief Richard Pazdur said he was pressured to endorse FDA messaging on reduced clinical‑trial requirements, telling reporters he was handed a press release and asked to "just agree to...
New algorithm builds near‑complete genomes without ultra‑long reads
Haoyu Cheng at Yale unveiled hifiasm (ONT), an algorithm that assembles near end‑to‑end human genomes using standard sequencing without needing ultra‑long DNA input. The tool reduces dependency on...
AI‑predicted insulin resistance tied to 12 cancers in UK Biobank
Researchers led by Yuta Hiraike at the University of Tokyo applied a machine‑learning tool (AI‑IR) to 500,000 UK Biobank participants and found insulin resistance is a risk factor for 12 cancer...
Systematic ligand diversification finds molecular glue that degrades leukemia driver
Researchers introduced a high‑throughput chemistry-plus‑cellular assay pipeline that diversifies ligands to discover molecular glues capable of inducing target degradation. The team focused on...
New oncology probes: KIF18A and KARS inhibitors enter IP and synthesis reports
Two preclinical programs reported novel inhibitors against cancer targets. Insilico Medicine disclosed KIF18A inhibitors with reported antitumor activity from synthesis and profiling studies....
Regulatory green lights: NMPA OKs Gensci‑136 trials; FDA clears CSPC IND
China’s NMPA authorized Changchun Genescience to begin clinical trials of Gensci‑136, a dual APRIL/BAFF antagonist for immunoglobulin A nephropathy (IgAN). The clearance enables the company to...
FDA rejects Disc’s rare-disease drug — biomarker questions
The FDA has issued a complete response letter to Disc Medicine, rejecting bitopertin for erythropoietic protoporphyria (EPP) and demanding additional clinical data. The agency questioned Disc’s...
FDA leadership clash — former officials and current chiefs at odds
Former FDA oncology chief Richard Pazdur told reporters he resigned after being pressured to endorse reduced clinical-trial requirements, saying he was handed a press release "with a quotation by...
Fujifilm opens UK mega‑CDMO — single‑use capacity expands
Fujifilm Biotechnologies opened an expanded biomanufacturing campus in Teesside, UK, backed by roughly £400 million in investment, creating what the company calls the largest single-use CDMO...
Algorithm assembles human genomes without ultra‑long reads
A team led by Haoyu Cheng at Yale School of Medicine introduced hifiasm (ONT), an algorithm that achieves near end-to-end human genome assembly using standard sequencing inputs, removing the need...